Zobrazeno 1 - 5
of 5
pro vyhledávání: '"L Quesada Muñoz"'
Autor:
M. Martín Rufo, M Muñoz García, A. Álvarez Díaz, C Palomar Fernández, Á Díaz Gago, L Quesada Muñoz, E. Delgado Silveira
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance During the March and April, over 700 patients were discharged from the emergency department (ED) in a third level hospital to home with treatment for COVID-19 Their characteristics and final outcomes remain unknown Aim and o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fd373ffdf72eca77f56ea3510c3c0ba
https://doi.org/10.1136/ejhpharm-2021-eahpconf.332
https://doi.org/10.1136/ejhpharm-2021-eahpconf.332
Autor:
MT Bermejo Vicedo, Má Rodríguez Sagrado, L Quesada-Muñoz, M Rodríguez Marín, M. Vélez-Díaz-Pallarés, N Vicente Oliveros, S Sanz Merino, B Montero Llorente, T Gramage Caro
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Recently, change from cobicistat to ritonavir is being promoted at a tertiary hospital for economic reasons. Therefore, there is a growing need to study what this switch may involve. Aim and objectives Our objective was to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::041fd0b37106343365c184f4323bed28
https://doi.org/10.1136/ejhpharm-2020-eahpconf.167
https://doi.org/10.1136/ejhpharm-2020-eahpconf.167
Autor:
M. Vélez-Díaz-Pallarés, A Cabello Bravo, E Vida Navas, L Quesada-Muñoz, A Cortés Salgado, T. Bermejo Vicedo, J Fernández Fradejas
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Due to its recent commercialisation, the safety profile of palbociclib is undergoing special surveillance. Tolerability and safety problems often lead to dose reductions, introduction of supportive treatment or even treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3079cbd1610453701a9ac50ecb9e4647
https://doi.org/10.1136/ejhpharm-2020-eahpconf.184
https://doi.org/10.1136/ejhpharm-2020-eahpconf.184
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Quesada Muñoz L; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Fernández-Fradejas J; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Martinez-Barros H; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain hilario.martinez@salud.madrid.org., Sánchez Cuervo M; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Martín Rufo M; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Pintor Recuenco MDR; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Quereda Rodríguez-Navarro C; Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Álvarez-Díaz AM; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain., Saez de la Fuente J; Pharmacy, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Publikováno v:
European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Oct 25; Vol. 31 (6), pp. 532-536. Date of Electronic Publication: 2024 Oct 25.